Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.47 |
| ▸ | CBFB | Q13951 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657673 | 0.93 | GCK (0.45) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1657541 | 0.87 | GCK (0.45) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1656692 | 0.87 | GCK (0.44) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1657346 | 0.84 | GCK (0.43) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1656745 | 0.84 | GCK (0.45) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1656441 | 0.83 | GCK (0.44) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1657596 | 0.83 | GCK (0.45) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1657280 | 0.83 | GCK (0.45) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL2646318 | 0.83 | CBFB (0.46) | GCKCBFBNPC1RAB9ARUNX1 | |
| SCHEMBL1657058 | 0.83 | GCK (0.45) | GCKCBFBNPC1RAB9ARUNX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810969-B1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | MSD KK (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-7932394-B2 | 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents | MSD K.K. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | GCK 1/4885CBFB 1380/4885NPC1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.